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ABSTRACT
Freiwan, Abdullah. M.S., Microbiology and Immunology Graduate Program, Wright State
University, 2014. Elucidating the effects of TCDD on the polymorphic human hs1,2 enhancer .

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a potent environmental toxin known to inhibit
immunoglobulin (Ig) gene expression in various animal studies. We have identified the mouse
3’Ig heavy chain regulatory region (3’IgH RR) as a sensitive transcriptional target of TCDD,
which may mediate the inhibitory effect of TCDD on Ig expression. Interestingly, the human
hs1,2 enhancer is polymorphic and has been associated with a number of autoimmune diseases.
Suggesting a species difference, TCDD inhibited mouse hs1,2 enhancer activation and activated
basal human hs1,2 (hs-hs1,2) enhancer activity in the mouse B-cell line. The objective of this
study was to elucidate the effects of TCDD on the polymorphic human hs1,2 enhancer using a
human B-cell line (CL-01) and luciferase reporter constructs regulated by each of the human
hs1,2 alleles. Our results verify that TCDD alone activates each of the hu-hs1,2 alleles.
Surprisingly, B-cell stimulation through the Toll-like receptors (TLR) 7, 8, and 9, and the AhR
antagonist inhibited basal activity of the hu-hs1,2 alleles and TCDD co-treatment reversed TLRinduced inhibition. Contrary to this, TLR stimulates IgM secretion as well as class switching to
IgG secretion. These results suggest that the hu-hs1,2 enhancer may be a negative regulator of
3’IgH RR activity and Ig expression.
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I. INTRODUCTION
2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD)
Dioxins or dioxin like compounds are highly toxic compounds that include
polyhalogenated aromatic hydrocarbons such as polychlorinated dibenzo-pdioxins (PCDD), polychlorinated dibenzofurans (PCDF), and polychlorinated
biphenyls (PCB) (Mandal, 2005). Dioxins have no common uses and are not
intentionally produced by industry but can be formed when organic material is
burned in presence of chlorine (from Cl- ion or an organochlorine compound).
This compound may be released to the environment during incineration of
municipal and medical waste, coal-fired utilities, metal smelting, diesel trucks,
burning treated wood, misapplication of sewage sludge, and bleaching of paper
fibres and textiles (Malisch & Kotz, 2014; Strucinski et al., 2011). The most
potent form of dioxin is TCDD (Mandal, 2005). In animals, one high dose of
TCDD causes systemic effects including tumorigenesis, immunological
dysfunction, and teratogenesis. Additionally, studies of humans exposed to TCDD
and supporting evidence from animal studies, suggest that TCDD induces
chloracne, inhibits the immune response, metabolic disorders (porphyria), and
other systemic problems as well as being a cancer promoter (Pohjanvirta &
Tuomisto, 1994). Acute toxicity studies have shown marked species differences in
sensitivity to TCDD. (Kociba & Schwetz, 1982).
TCDD is a polychlorinated dibenzo-p-dioxin with a chemical formula of
C12H4Cl4O2 (Fig. 1). Generally, people could be exposed to TCDD through soil,
1

dust, and smoke by inhalation or consumption (Braune, Mallory, Butt, Mabury, &
Muir, 2010). TCDD achieved notoriety when it was discovered to be a
contaminant in the herbicide Agent Orange, which was used in the Vietnam War
(1961-1971). In 1976, thousands of inhabitants of Seveso, Italy were exposed to
TCDD after an accidental release of several kilograms of TCDD from a pressure
tank (Mandal, 2005). Moreover, in 1997, two women from Vienna were poisoned
with TCDD at their workplace and the measured concentration, (144 ng/g of fat),
in one of them was the highest ever measured in a human being. Besides
chloracne, they did not present with major clinical health effects within the first
two years after TCDD intoxication (Geusau et al., 2001). In 2004, following an
assassination attempt during his election campaign, Viktor Yushchenko was
exposed to TCDD, at a concentration of 108 ng/g of fat. He was diagnosed him
with gastritis, colitis with multiple ulcers, hepatitis, pancreatitis, and chloracne as
a result of the poisoning (Sorg et al., 2009). In general, studies on the health
effects in humans from exposure to TCDD show no threat to life. However,
effects that are not overtly toxic or are long term consequences of exposure may
occur and be difficult to measure or directly link to dioxin exposure (i.e. increased
infections, cancer etc.) (Pelclova et al., 2006). The biological effects of TCDD are
thought to be mediated by the aryl hydrocarbon receptor (AhR).
.
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Figure 1: Chemical structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
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Aryl Hydrocarbon Receptor Signaling Pathway
The aryl hydrocarbon receptor (AhR) is a constitutively expressed
transcription factor that is encoded by the AhR gene and consists of 848 amino
acids. It regulates xenobiotic metabolizing enzymes such as cytochrome P450.
AhR is an inactive cytosolic protein belonging to the basic helix-loop-helix/PerARNT-Sim (bHLH/PAS) family of transcription factors (Abel & HaarmannStemmann, 2010; Nebert & Karp, 2008). The AhR binds to ligands that include;
(1) chemicals including aromatic environmental pollutants and several
pharmaceuticals, (2) endogenous ligands or, (3) synthetic and compounds
(Denison & Nagy, 2003; Nebert & Karp, 2008; Strucinski et al., 2011; Whitlock,
1999).
In the absence of a ligand such as TCDD, AhR stays in the cytoplasm in
an inactive form bound to a multi-protein complex which consists of a dimer of
HSP90, co-chaperone p23, and XAP2. In order to stabilize the whole complex,
XAP2 binds with AhR and HSP90, while p23 directly binds to HSP90 and plays
an essential role in the process of AhR activation (Whitlock, 1999) (Fig 2). Upon
ligand binding, the AhR protein undergoes conformational changes and
dissociates from the multi-protein complex. The AhR then translocates into the
nucleus and binds to the AhR nuclear translocator (ARNT) forming the
heterodimer complex, TCDD-AhR/ARNT (Abel & Haarmann-Stemmann, 2010).
The TCDD-AhR/ARNT heterodimer complex is transcriptionally active and binds
to dioxin responsive elements (DRE) in the promoter and enhancer regions of
target genes resulting in alterated gene expression. The AhR protein can be
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downregulated by either negative feedback inhibition or ubiquitination. Negative
feedback inhibition is mediated by the AhR repressor or nuclear export of the
receptor by proteosomal degradation (Abel & Haarmann-Stemmann, 2010). The
induction of cytochrome P4501A1 (Cyp1a1) has been used as a biomarker for
AhR activation (Hansen, Esakky, Drury, Lamb, & Moley, 2014; Hu, Sorrentino,
Denison, Kolaja, & Fielden, 2007; Whitlock, 1999). Furthermore, up-regulation
of metabolic enzymes by TCDD led to the discovery of the AhR and its signaling
pathway and the succeeding efforts to determine if the AhR was responsible for
the toxic effects of TCDD (Delescluse, Lemaire, de Sousa, & Rahmani, 2000).
The AhR also appears to play an important role in mediating most of the toxic and
carcinogenic effects of TCDD and other dioxins (Dertinger, Nazarenko,
Silverstone, & Gasiewicz, 2001). The AhR also has roles in steroid hormone
metabolism, cellular proliferation and differentiation, and cell death. The immune
system has also been identified as a sensitive target of TCDD and various
components of the immune system are affected, including the differentiation of B
cells into antibody forming cells (Zhang et al., 2013).
.
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Figure 2: Aryl hydrocarbon receptor signaling pathway. Dioxin binds to the AhR to
initiate a series of events leading to modulation of gene expression. CYP1A1 is a
sensitive indicator of AhR activation.
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The Immune system
The immune system is a network of cells, tissue, and organs that works together
to defend the body against foreign invaders. The human body provides a perfect
environment for many microbe, such as bacteria, viruses, fungi, and parasites. The
immune system, which is crucial to human survival, prevents and limits the microbial
entry and growth. The immune system is classified into innate and adaptive immune
system.
Innate immunity is always present and ready to fight microbes at the site of
infection. It is the first line of defense and employs a non–specific response against
pathogens. The main components of innate immunity include physical barriers,
phagocytes (such as macrophages, dendritic cells, and neutrophils), and natural killer
cells. On the other hand, adaptive immunity is an antigen-specific defense. Both innate
and adaptive immunity often work together and there is a lot of crossover between the
two mechanisms. Adaptive immunity eliminates specific antigens by either antibodymediated immunity or cell-mediated immunity. Antibody-mediated immunity involves
the production of antibody molecules in response to an antigen and is mediated by B
cells, while cell-mediated immunity involves the activation of cytotoxic T-lymphocytes
in response to an antigen and is mediated by T cells.
T cells either express CD4 or CD8 co-receptors. The CD4+ T cells are essential
for both antibody-mediated immunity and cell-mediated immunity, and bind to epitopes
presented by class II major histocompatibility complex (MHC II). The MHC II molecules
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normally found only on antigen-presenting cells (macrophage, dendritic cells, and B
cells) and are specialized to fight extracellular sources of the infection such as bacteria.
Alternatively, CD8+ T cells bind to epitopes presented by a class I MHC and secrete
molecules that destroy the cell to which they have bound. The MHC I molecules are
expressed by nearly every nucleated cell of the body and are specialized to fight
intracellular infections such as viruses.
B cells
B cells, or B lymphocytes, are essential in the humoral immune response of the
adaptive immunity. B cells are produced from the bone marrow and then migrate as
mature cells to the spleen and other secondary lymphoid tissue. B cell receptors (BCR)
are transmembrane receptor proteins located on the outer surface of B-cells that interact
with antigen. In order to activate B cells, the cells need a secondary activation signal
provided by either the antigen itself or helper T cells. After stimulation, B cells
eventually undergo proliferation and differentiation to plasma cells that secrete
antibodies. The antibody, or secreted immunoglobulin (Ig), is used by the immune system
to identify and neutralize foreign antigens such as bacteria and viruses. Ig is composed of
two identical heavy chains (H) and two identical light chains (L) connected together by
disulfide bonds (Fig 3). Antibodies can be divided into five different effector classes
(IgM, IgG, IgA, IgD, IgE). The heavy chains differ in structural and functional
properties, and determine the class and subclass of antibodies. The two isotypes of light
chains are either kappa or lambda; however there are no significant differences between
them.
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V(D)J recombination, also known as somatic recombination, is a mechanism of
genetic recombination specific to B cells that takes place in bone marrow and randomly
combines three gene segments (V, D, J) of the IgH gene and two segments (V, J) of the
IgL gene to encode for the variable region of the heavy and light chain, respectively.
Maturation of immature B cells to mature B cells produces membrane-bound IgM and
IgD, whereas the B cells that fail to pass any of the maturation steps will die by
apoptosis. Production of Ig can also involve the transition to expressing different classes
of antibodies.
Following maturation B cells stay in the peripheral tissues until they encounter an
antigen and are activated. Upon activation, B cells differentiate into plasma cells or
memory B cells. Plasma cells can secrete huge amounts of Ig every minute for several
days. A large amount of antibody is released into the circulation to respond to the
infection. The initial burst of antibody production progressively decreases as the stimulus
is removed (e.g., by recovery from infection). However, some antibody continues to be
present for several months afterward. Alternatively, memory B cells are long-lived
lymphocytes that have previously encountered a given antigen. When B is re-exposed to
the same antigen, it rapidly initiates an immune response, and then B cells will proliferate
and produce large amounts of specific antibodies, memory B, against the agent and
therefore providing lasting immunity.
Class switch recombination (CSR) is a biological mechanism that changes a B
cell’s expression of Ig from one class to another. CSR occurs after activation of a mature
B cell. As a result of helper T cell recognition of antigen on the B cell surface through
MHC II, the T cell becomes activated and provides a secondary stimulus to B cell to
9

differentiate into IgM producing cells. Furthermore, the B cell can undergo antibody class
switching to produce IgG, IgA or IgE antibodies. During this process, the constant region
of the heavy chain is changed, whereas the variable region stays the same, meaning the
class switch is limited to changing the heavy chain only, so CSR will not affect antigen
specificity. The variable region of heavy and light chain determines antigen specificity
where the population of antibody molecules are able to react with only one antigen.

Variable Variable
Constant

Light Chain

Disulfide bond

Heavy Chain

Figure 3: Immunoglobulin (Ig) structure. Secreted Ig (antibody) is composed of a
heavy chain and light chain that binds a specific antigen. Each chain contain constant
region that determines the effector qualities of the Ig and a variable region that binds
antigens.
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TCDD-Induced Immunological Effects
The immune system is a sensitive target of TCDD. The effects of TCDD
in experimental animals include suppression of both innate and adaptive immune
responses and decreased host resistance to infectious agents (Morris & Holsapple,
1991; Safe, 1998). The majority of effects have been reported based on either
accidental exposures or in vitro analysis. However, humans seem to be less
sensitive to immunotoxic effects by TCDD than many laboratory animals (Okey,
Riddick, & Harper, 1994). TCDD-induced immunological effects on human
beings include severe skin rash called chloracne, effects on thymus cells such as
human thymic epithelial cells (TEC) which affects immune response, porphyria,
transient hepatotoxicity, peripheral and central neurotoxicity, and signiﬁcant
decrease in IgG levels (Dertinger et al., 2001; Silbergeld & Gasiewicz, 1989). In
addition, there are some effects of TCDD on human serum such as elevations in
GGT and triglyceride levels, and alterations in FSH and LH (Sweeney &
Mocarelli, 2000). TCDD-induced immunotoxicity such as suppression B
development and

decrease antibody secretion

is mediated by the aryl

hydrocarbon receptor but the mechanism is still unclear (Hansen et al., 2014).
Moreover, previous studies showed that the affinity of TCDD binding to the AhR
is much lower in human than in animals and that might explain why humans seem
to be less sensitive to immunotoxic effects by TCDD than many laboratory
animals (Okey et al., 1994).
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TCDD-Induced B cell Dysregulation
The B cell is a sensitive and direct cellular target of TCDD (Sulentic,
Holsapple, & Kaminski, 1998). B cell differentiation into antibody forming cells
is significantly inhibited by TCDD in various animal models and this effect
appears to be AhR-dependent (Mimura & Fujii-Kuriyama, 2003; Sulentic et al.,
1998). TCDD-induced suppression of mouse B cell maturation, activation, and
differentiation is mediated by the immunoglobulin heavy chain (IɡH) locus
(Fernando, Ochs, Liu, Chambers-Turner, & Sulentic, 2012; Sulentic et al., 1998).
Inhibition of antibody secretion can occur either with or without T-helper
function. B cells can be activated via lipopolysaccharide, LPS, (T-cell
independent) or sheep red blood cells (T-cell dependent) (Holsapple, Dooley,
McNerney, & McCay, 1986). Furthermore, mouse B cells (CH12.LX) activated
by LPS increase AhR expression, which may increase the ability of AhR to bind
to TCDD and increase the sensitivity of B cells to TCDD (Sulentic et al., 1998).
One study showed that TCDD decreases IgM secretion under LPS stimulation in
AhR expressing mouse B cells (CH12.LX), while it did not inhibit IgM secretion
when activated by LPS in AhR-deficient mouse B cells (BCL-1), implicating an
important role for AhR in inhibition of B cells by TCDD (Sulentic et al., 1998).
Another research study confirmed that knocking down AhR or using an AhR
antagonist in an IgA secreting mouse B cell line reduced TCDD-induced
inhibition IgA secretion, which adds more evidence that AhR plays an essential
role in inhibition of Ig expression by TCDD (Sulentic , data not published).
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Immunoglobulin Heavy Chain (IɡH) Locus
The human Iɡ heavy chain (IɡH) locus is located on chromosome 14,
encodes the heavy chains of human antibodies, and undergoes VDJ
recombination, class switch recombination (CSR), and somatic hypermutation
(SHM) (Pinaud et al., 2011). A rearranged IɡH gene is comprised of the variable
heavy chain promoter (VH), VDJ region, intronic enhancer (Eµ), heavy chain
constant region (CH) with germline promoters, and the 3’ immunoglobulin heavy
chain regulatory region (3’IɡHRR) (Mills, Harindranath, Mitchell, & Max, 1997)
(Fig 4). The VH promoter initiates transcriptional regulation of the IɡH, while the
VDJ encodes the antigen binding site. The intronic enhancer (Eµ) is necessary for
efficient V to DJ joining and Cµ expression. The mouse 3’IɡhRR, located
downstream of the Iɡh locus, is a key regulator of the Iɡh locus and plays an
important role in modulating the transcription of the Iɡh gene, and CSR but does
not affect VDJ rearrangement (Cogne et al., 1994; Ju, Chatterjee, & Birshtein,
2011). There are some differences between the 3’IɡHRR in the mouse and human.
While the mouse has one 3’IɡhRR that contains four enhancers (hs3a; hs1,2;
hs3b; hs4) that display DNase I hypersensitivity, the human 3’IɡHRR has two
regulatory regions, α1 3’IɡHRR and α2 3’IɡHRR, and each of these regions has
three enhancers (hs3; hs1,2; hs4) (Chauveau & Cogne, 1996; Mills et al., 1997;
Sepulveda, Emelyanov, & Birshtein, 2004; Sepulveda, Garrett, Price-Whelan, &
Birshtein, 2005).
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In the mouse, the 3’IɡhRR was identified as a sensitive transcriptional
target of TCDD, which may mediate the inhibitory effect of TCDD on Ig
expression (Sulentic, Holsapple, & Kaminski, 2000). The 3’IɡHRR has stronger
activity in surface Ig B cells and plasma cells than in pre-B cells (Ong, Stevens,
Roeder, & Eckhardt, 1998). Utilizing the CH12LX mature B-cell line, TCDD
suppresses the mouse 3′IghRR activation and Ig secretion, and induces AhR
binding to dioxin response elements (DRE) within the 3′IɡHRR hs1,2 and hs4
enhancers (Sulentic, Kang, Na, & Kaminski, 2004). In addition, antagonist studies
supported an aryl hydrocarbon receptor-dependent inhibition of 3′IɡHRR
activation (Sulentic, data not published). The mouse enhancer hs1,2 is the most
active enhancer within 3’IɡHRR’s enhancers in mature B cells and plasma cells
whereas the hs3 enhancer has slight and hs4 has modest activity in activated B
cells (Chauveau, Pinaud, & Cogne, 1998; Saleque, Singh, & Birshtein, 1999).
Moreover, the hs1,2 and hs4 enhancers are regulated by many different
transcription factors such as NFkB, Oct, and Pax5. Overall, the enhancers of
3’IɡH RR display stronger synergistic activity when they are together than they
do individually (Ong et al., 1998; Stevens, Ong, Kim, Eckhardt, & Roeder, 2000).
Previous studies have demonstrated a species difference in the effects of TCDD
on hs1,2 enhancer activity. TCDD inhibits mouse hs1,2 enhancer activation,
which correlates with the inhibitory effects of TCDD on mouse 3’IghRR and Ig,
while TCDD activates the human hs1,2 enhancer, which is contradictory to the
inhibitory effects of TCDD on mouse Ig expression (Fernando et al., 2012).
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In humans, a polymorphism of the hs1,2 enhancer in the 3’IɡHRR has
been associated with Burkitt’s lymphoma and many different human immunerelated disorders such as IgA nephropathy, celiac disease, systemic sclerosis,
plaque psoriasis, psoriatic arthritis, dermatitis herpetiformis, and rheumatoid
arthritis (Aupetit et al., 2000; Cianci et al., 2008; Pinaud et al., 2011; Tolusso et
al., 2009). The B cell malignancies, such as human Burkitt’s lymphoma, contain a
chromosomal translocation between proto-oncogenes, c-myc and bcl-2, and the
3’IɡHRR which induces c-myc and bcl-2 deregulated gene expression and
increases resistance to cell death (Heckman et al., 2003).

Figure 4: Human and mouse immunoglobulin heavy chain (IɡH) gene locus.
VH, variable heavy chain promoter; Eμ, intronic or μ enhancer; open rectangles,
germline promoters upstream of each heavy chain constant region.
15

The hs1,2 Human Polymorphic Enhancer.
The human 3’ IɡHRR contains three transcriptional enhancers called hs3,
hs1,2 and hs4 that are located downstream of the 3’IɡH locus (Fig. 4). Among
them, the human hs1,2 enhancer plays a critical role in the control of transcription
and is considered the strongest the three enhancers (Cogne et al., 1994; Guglielmi,
Truffinet, Magnoux, Cogne, & Denizot, 2004). Although the mouse and human
hs1,2 enhancers share about 90% similarly in DNA sequences, there are some
notable differences between them (Mills et al., 1997). These differences may
explain the diverse behaviors of both human and mouse hs1,2 enhancers under the
effect of TCDD. TCDD inhibits the mouse hs1,2 enhancer while it activates the
human hs1,2 enhancer in both a mouse and human B-cell line (Fernando et al.,
2012). Interestingly, Paired box protein (Pax5), an important regulator of B cell
development and differentiation, highlights the most notable difference between
the human and mouse hs1,2 enhancer (Fig 5). While the human hs1,2 enhancer
does not have Pax5, the mouse hs1,2 enhancer contains two copies of Pax5
binding sites (Schneider, Manzan, Yoo, Crawford, & Kaminski, 2009). Pax5 is a
negative regulator of B-cell differentiation into antibody secreting cells and this
may explain the divergent effects of TCDD between the human and mouse hs1,2
enhancer.
The human α1 hs1,2 enhancer is polymorphic and contains one to four
copies of an invariant sequence (IS) of 53 bp. The invariant sequence (IS) could
be repeated one (α1A), two (α1B), three (α1C), or four (α1D) times and each repeat
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has several binding sites for transcription factors such as AP-1, SP1, NF-κB, and
DRE (Denizot et al., 2001; Mills et al., 1997). Previous research has shown that
an increase in the number of 53 bp repeats may result in an increase in sensitivity
to TCDD (Fernando et al., 2012). Polymorphisms in the human hs1,2 enhancer
correlate with a number of immune disorders, such as plaque psoriasis, psoriatic
arthritis, systemic sclerosis lupus, rheumatoid arthritis, coeliac disease,
herpetiform dermatitis, and IgA nephropathy. Of the different hs1,2 alleles, α1B
significantly correlates with increased severity of these diseases (Aupetit et al.,
2000; Cianci et al., 2008; Pinaud et al., 2011; Tolusso et al., 2009). Furthermore,
past studies have shown that the allelic frequency of all four alleles of the hs1,2
enhancer is distributed differently among ethnic populations suggesting the hs1,2
polymorphism may be considered a reliable anthropogenetic marker. For
example, α1B has the highest frequency among Asian and Europeans, α1C and α1D
alleles are at their highest frequencies among Africans (Giambra et al., 2006).
Elucidating the role of the polymorphic hs1,2 enhancer in 3’IɡHRR activity and
the effect of TCDD on the enhancers of the 3’IɡHRR may provide insights into
the etiology of autoimmune diseases associated with the hs1,2 polymorphism.
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Figure 5: Comparison of DNA sequences for the human and mouse hs1,2
enhancers with predicted transcription factor binding sites.
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Significance, Objectives, and Hypothesis
A previous study showed the activation of the human hs1,2 enhancer by TCDD
using a mouse B-cell line (CH12.LX) and a human B-cell line (IM-9) (Fernando et al.,
2012). In the IM-9 human cell line, cells could not be activated with either R848, a ligand
for TLR 7/8, or CpG, a ligand for TLR 9 whereas LPS, a ligand for TLR 4, stimulated the
basal activity of the human hs1,2 enhancer and antibody secretion in the mouse cell line,
CH.12LX. Activating B cells is very important for differentiation into plasma cells and
production and secretion of antibodies IgD and IgM with lipophilic tail are constitutively
expressed in mature, unactivated B cells. For this project, I am using a different cell line
Cl-01 that was isolated from a Burkitt’s lymphoma patient and has antigen specificity to
human monoclonal B cell line that expresses surface IgM and IgD. CL-01 cells can
undergo somatic hypermutation and Ig class switching in vitro, which makes the CL-01
cell line a better model for in vitro studies of human B cell differentiation and CSR
(Cerutti et al., 1998). The CL-01 cell line should offer a suitable model to study the
effects of TCDD on the hs1,2 alleles and correlate these effects with Ig expression and
CSR. Based on preliminary data, my hypothesis is that the AhR is a significant positive
regulator of the human hs1,2 enhancer and that the hs1,2 enhancer is a negative regulator
of 3’IɡHRR activity and Ig expression. In order to test this hypothesis, I had three
objectives. Objective one was to determine the effect of TCDD on enhancer activity of
the human hs1,2 alleles. Objective two was to determine the effect of B cell stimulation
by R848 and CpG on enhancer activity of the human hs1,2 alleles. Objective three was to
determine what role the AhR plays in TCDD’s effects on the activity of the human hs1,2
alleles.
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The current study has significant implications for several reasons. First of all,
the human hs1,2 enhancer is polymorphic and has been associated with a number of
autoimmune diseases such as dermatitis herpatiforms, plaque psoriasis, psoriatic arthritis,
systemic sclerosis, coeliac disease, rheumatoid arthritis, lupus, sclerosis, schizophrenia,
and IgA nephropathy. Elucidating the role of the polymorphic hs1,2 enhancer in
3’IɡHRR activity and the effect of TCDD on the enhancers of the 3’IɡHRR may provide
insights into the etiology of autoimmune diseases associated with the hs1,2
polymorphism as well as greater understanding of Ig regulation in general. Secondly,
studying the human polymorphic hs1,2 enhancer as a part the 3’IɡHRR is very important
since

3’IɡHRR is related to chromosomal translocations that lead to result in an

oncogene (i.e. c-myc or bcl2) under the transcriptional regulation of the 3'IghRR leading
to specific cancers, such as Burkitt's and diffuse large cell lymphoma. Finally, studying
the AhR’s role in human hs1,2 enhancer activity is important in assessing risk of human
exposure to AhR ligands and potentially offering new therapeutic avenues for diseases
associated with the 3'IghRR.
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II. MATERIALS AND METHODS
Chemicals and Reagents
TCDD, dissolved in 100% dimethyl sulfoxide (DMSO), was purchased from
Accustandard Inc. (New Haven, CT). This product has a certificate of analysis that
reports 99.1% purity. DMSO was purchased from Sigma-Aldrich (St. Louis, MO). The
AhR antagonist (CH-223191), dissolved in 100% DMSO, was purchased from
Calbiochem (Carlsbad, CA). R848, a TLR 7/8 ligand, was purchased from Enzo Life
Sciences and was dissolved in water. CpG, a TLR 9 ligand, was purchased from Eurofins
MEG Operon (Huntsville, AL) and was dissolved in water.
Cell Line Model
The CL-01 human B-cell line that was utilized in all experiments and isolated
from a Burkitt’s lymphoma patient. The CL-01 cell line is a non-antigen specific human
monoclonal B cell line that expresses surface IgM and IgD. Moreover, CL-01 cells can
undergo somatic hypermutation, and CSR in vitro, which makes CL-01 a better model for
in vitro studies of human B-cell differentiation and CSR (Cerutti et al., 1998).
Cell Culture Conditions
The CL-01 cell line was grown in RPMI 1640 medium (Mediatech, Inc.,
Manassas, VA) supplemented with 10% bovine calf serum (Hyclone Laboratories,
Logan, UT), 13.5 mM HEPES, 23.8 mM sodium bicarbonate, 100 units/mL penicillin,
100 μg/ml streptomycin, 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, 2
mM L-glutamine, and 50 μM β-mercaptoethanol. Cl-01 cell line was maintained at 37°C
in an atmosphere of 5% CO2 for 24 hours.
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Reporter Plasmid Constructs
Human polymorphic hs1,2 reporter plasmids (α1A, α1B, α1C, and α1D) were
generously provided by Dr. Michel Cogne (Laboratoire d’Immunologic, Limoges,
France). As described previously, the human polymorphic hs1,2 reporter plasmids
contain the variable heavy chain promoter and either one (α1A), two (α1B), three (α1C) or
four (α1D) repeats of the 53 bp invariant sequence (IS) (Fig 6) (Denizot et al., 2001). The
human polymorphic hs1,2 reporter plasmids utilize the pGL3 basic luciferase reporter
construct (Promega, Madison, WI) containing ampicillin resistance and the luciferase
gene.
Site-directed Mutagenesis
Site-directed mutagenesis was performed on the α1D human hs1,2 luciferase
reporter construct according to the QuikChange XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) to avoid a confounding contribution of a DRE within the
multiple cloning site (MCS) of pGL3 the backbone as described previously (Fernando et
al., 2012) Oligonucleotide primers (Table 1) were designed to delete the DRE binding
motif in the multiple cloning site. The deletion reaction used 5 μl of 10X reaction buffer,
100 ng of genomic DNA extracting from CL-01 cell line, 1 μl of dNTP mix, 125 ng each
of forward and reverse mutation primers, 1.5 μl of QuikSolution reagent, and ddH2O to a
final volume of 50 μl in PCR tubes. This was followed by adding 1 μl of QuikChange
Lightning Enyzme before placing the tubes on thermal cycling machine. PCR conditions
were 95º C for 2 min followed by 18 cycles at 95º C for 20s, 60º C for 10s, 68º C for 2
min and 30 sec (30 sec/kb of plasmid length), then 68º C for 5 min. Following the PCR
reaction, 2 μL of the Dpn I restriction enzyme was added to each 50 μL reaction and
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incubated at 37ºC for 5 minutes. 2 μl of Dpn I-treated DNA was transformed into 45 μl of
XL10-Gold® ultracompetent cells (Retrogen, Inc., San Diego, CA).
Forward Primer
Template sequence
Reverse Primer

GGTACCGAGCTCTTAC------------CTAGCCCGGGC
CCGAGCTCTTACGCGTGCTAGCCCGGG
CCCGGGCTAGG------------TAAGAGCTCGGTACC

Table 1: Oligonucleotide primers for site-directed mutagenesis to remove
MCS-DRE from α1D hs1,2 reporter. Primers are italicized, and the MCS-DRE in bold
is deleted.

Transient Transfection
CL-01 cells (1.0 x 107) were pelleted by centrifugation at 500 x g for 5 minutes at
4° C. The pellet was re-suspended with 10 μg of plasmid and enough complete medium
to make the final volume 200 μl. The 200 μl mixture was transferred to a 2mm
electroporation cuvette and electroporated at 150 V, 1500 μF, and 75 ohms. For each
plasmid, multiple transfection cuvettes were pooled and diluted to a seeding
concentration of 1 x 105 cells/ml, then treated as follows: naïve (NA), 0.01% DMSO
vehicle (0 nM TCDD), or TCDD (0.03 nM, 0.3 nM, 3 nM, 30 nM) in the absence or
presence of R848 (1 μg/mL) or CpG (5 nM) stimulation. Cells were aliquoted into 12well plates, each well contained 2 ml of pooled transfected cells (n=3) and was incubated
at 37°C in 5% CO2 for 24 hours. In the AhR antagonist experiments (AHRA), we treated
as follows: naïve (NA), 0.05% DMSO vehicle (0 nM AhR), or AhR (30 μM) in the
absence or presence of R848 (1 μg/mL). Cells were pre-treated with 30 μM AhRA and
incubated at 37°C in 5% CO2 for 1 hr before adding other treatments. Following a 24 hr
of incubation, the cells were pelleted and lysed with 1x reporter lysis buffer (Promega),
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then immediately frozen at -80°C for a minimum of 2 hours. To measure luciferase
enzyme activity, samples were thawed on ice and centrifuged at 14000 x g for 5 minutes
at 4°C then100 μl of luciferase substrate (Promega) was mixed with 20 μl of sample
lysate in a glass tube and luminescence (luciferase activity) was measured by a Sirius
luminometer (Berthold Detection Systems, Oak Ridge, TN) and presented as relative
light units (RLU)
Transfection Efficiency
To determine the transfection efficiency, as previously described Sulentic et al., 2004,
we measured the number of plasmids per cell using quantitative real-time PCR. DNA was
isolated using a genomic DNA extraction kit (Sigma Aldrich) from naïve cells. TCDD
and cellular activation treatments do not affect transfection efficiency (Sulentic, Zhang,
Na, & Kaminski, 2004). Two hours following transfection, the DNA was diluted 10-fold
and 2 μl was mixed with 12.5 μl 2x SYBR Green (Applied Biosystems, Warrington,
UK),

1

μl

10

pmol/μl

forward

primer-pGL3

luciferase

(5’-

ACTGGGACGAAGACGAACACTT-3’), 1 μl 10 pmol/μl reverse primer-pGL3
luciferase (5’-TCAGAGACTTCAGGCGGTCAA-3’), and 8.5 μl purified water. Samples
were compared to a standard luciferase reporter plasmid (α1A) with concentrations
ranging from 0.1 ng/μl to 1x106 ng/μl. The plasmid number per cell was calculated using
the following equation: (ng of plasmid) x (molecules of plasmid/ng of plasmid) /cell
number,. Luciferase activity was normalized to the control plasmid based on plasmids per
cell.
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Statistical Analysis of Data
A one way ANOVA followed by a Dunnett’s Multiple Comparison post test was
used to analyze the treatments groups (n=3) for significant differences to the appropriate
vehicle control “*”, “**”, “***” represent significance at p<0.05, p<0.01 and p<0.001,
respectively. A two way ANOVA followed by a Dunnett’s Multiple Comparison post test
was used to analyze significant differences between different plasmids. Results are
represented as either relative light units (RLU) normalized to transfection efficiency or
fold-change relative to the appropriate vehicle control. The mean fold-change ± S.E. was
determined by averaging the means from four to five separate experiments.

Figure 6: Human polymorphic hs1,2 reporter plasmid constructs. The asterick (*)
represents the IS that may be present one (α1A), two (α1B), three (α1C) or four (α1D) times.
VH, variable heavy chain promoter
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III. RESULTS
TCDD activates the human polymorphic hs1,2 enhancer in the CL-01 human B cell
line
CL-01 cells were transiently transfected with luciferase reporter plasmids
containing the human polymorphic hs1,2 enhancer (α1A, α1B, α1C, and α1D), then treated
with different concentrations of TCDD (0.03-30 nM). Luciferase reporter results were
normalized to transfection efficiency as determined by quantitative real-time PCR
targeting the luciferase gene. Expectedly, TCDD significantly activated the human
polymorphic hs1,2 enhancer (α1A, α1B, α1C, and α1D) in a concentration-dependent manner
(Fig.7 A). On the other hand, TCDD inhibited IgM and IgG secretion (Brooke Johnson,
data not published). The fold change of TCDD-induced activation for each luciferase
reporter plasmid (α1A, α1B, α1C, and α1D) was relatively similar (Fig.7 B) Whereas
increase in the number of invariant sequences doesn’t greatly impact TCDD-induced
activation (Fig.7 C). Each repeat of IS has several binding sites for transcription factors
such as AP-1, SP1, NF-κB, and DRE (Denizot et al., 2001; Mills et al., 1997). Increasing
the number IS will raise the chance for AhR-TCDD to bind to more transcription binding
sites within the IS’s and makes stronger effect of TCDD on the basal activity of human
hs1,2 enhancer. Therefore, the effect of both R848 and TCDD was evaluated on the
human polymorphic hs1,2 enhancer by utilizing reporter plasmids (α1A, α1B, α1C, and α1D)
(Fig. 8). Interestingly, the basal transcriptional activity in human CL-01 cells increased
with increasing number of IS repeats up to three (α1A, α1B, and α1C), while the basal
activity of four IS repeats (α1D) was similar to the basal activity of two IS repeats (α1B).
Unexpectedly, R848 stimulation inhibited the basal activity of each hs1,2 allelic reporter
(Fig 8). Previous studies have shown increases in basal activity of the human
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polymorphic hs1,2 enhancer that correlated with an increased number of these 53 bp
sequences for (α1A, α1B, and α1C) (Mimura & Fujii-Kuriyama, 2003).
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Figure 7: TCDD activates the human polymorphic hs1,2 enhancer in the CL-01
human B cell line and an increase in the number of invariant sequences doesn’t
greatly impact TCDD-induced activation. CL-01 cells were transiently transfected with
α1A, α1B, α1C, or α1D luciferase reporter plasmids. Transfected cells were either cultured in
the absence of any additional treatment (naïve, NA) or treated for 24 h with 0.01%
DMSO vehicle (0 nM TCDD) or TCDD (0.03-30.0 nM). (A) Luciferase enzyme activity
(mean SEM, n=1) is represented on the y-axis as relative light units (RLU) normalized to
transfection efficiency. (B) TCDD-induced activation (mean SEM, n≥3) is represented on
the y-axis as fold change relative to the vehicle control (0 nM TCDD). (C) TCDDinduced activation is represented on the y-axis as fold change relative to the appropriate
vehicle control. Comparisons between treatment groups were analyzed using a 1-way
ANOVA for A and B followed by a Dunnett’s Multiple Comparison post test . Asterisks,
“*”, “**”, or “***” denote significance compared to the corresponding vehicle set to 1 at
p<0.05, p<0.01 or p<0.001, respectively. For C, followed by a Dunnett’s Multiple
Comparison post test .
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Figure 8: The basal activity of human hs1,2 enhancer increased with increasing
number of IS repeats up to three (α1A, α1B, and α1C), while the basal activity of
four IS repeats (α1D) was similar to the basal activity of two IS repeats (α1B). The
CL-01 cells were transiently transfected with the α1A, α1B, α1C, and α1D reporter plasmids.
Transfected cells were either cultured in the absence of any additional treatment (naïve,
NA) or treated for 24 hr with 1.0 μg/mL R848. Luciferase activity is represented on the
y-axis as relative light units normalized to transfection efficiency (n≥3). Comparisons
between the treatment groups were analyzed using a one-way ANOVA followed by a
Dunnett’s two-tailed t-test. Asterisks, “*”, “**”, or “***” denote significance compared
to α1A at p<0.05, p<0.01 or p<0.001, respectively. Comparisons between unstimulated
and R848 stimulated of each plasmid was analyzed using a two-way ANOVA followed
by a Bonferroni’s two-tailed t test. “†”, “††”, and “†††” denote significance compared
with the unstimulated at p<0.05, p<0.01 or p<0.001, respectively.
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Cellular stimulation inhibits basal hs1,2 activity but TCDD co-treatment reverses
this inhibition
To better characterize the effects of cellular stimulation on hs1,2 activity, we
evaluated the concentration-dependent effects of R848 on the α1B hs1,2 reporter in the
CL-01 cells with varying concentrations of R848 (0.1 - 10 μg/mL). R848 inhibited the
basal activity of the α1B hs1,2 enhancer reporter in a concentration-dependent manner
(Fig 9). However, 1ug/mL R848 induces IgM and IgG stimulation (Brooke Johnson,
unpublished data). Therefore R848 is inducing cellular activation of the CL-01 cells,
perhaps suggesting that the hs1,2 enhancer is a negative regulator of the 3'IgHRR.
Another possibility is that the cells have not reached a sufficient cellular activation phase
when the luciferase is read. Recall early work of Roeder showing a dichotomy in the
regulation of hs1,2 that was stage dependent.
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Figure 9: R848 inhibit basal activity of α1B hs1,2 enhancer. CL-01 cells were
transiently transfected with the α1B luciferase reporter plasmid. Transfected cells were
either cultured in the absence of any additional treatment (naïve, 0 μg/ml) or stimulated
for 24 h with R848 (0.1 - 10 μg/ml). Luciferase enzyme activity (mean SEM, n=3) is
represented on the y-axis as relative light units normalized to transfection efficiency.
Comparisons between treatment groups were analyzed using a 1-way ANOVA followed
by a Dunnett’s Multiple Comparison post test. Asterisks, *, **, or *** denote
significance compared corresponding vehicle at p<0.05, p<0.01 or p<0.001, respectively
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R848 stimulates B cells by targeting TLR 7/8 to increase immunoglobulin
levels (Tomai, Imbertson, Stanczak, Tygrett, & Waldschmidt, 2000). However, having
such an unexpected inhibitory effect of R848 on the activity of the human hs1,2
enhancers led us to check whether R848 can activate NFkB, a universal endpoint of TLR
activation. The CL-01 cells were transiently transfected with a luciferase reporter
regulated by three NF-kB binding motifs. R848 increased 3X NF-κB activation indicating
that R848 is able to activate TLRs individually even though it inhibits overall activity of
the hs1,2 enhancer (Fig 10).
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Fig. 10: R848 activates a 3x NF-κB luciferase reporter in the CL-01 human
B-cell line. CL-01 cells were transiently transfected with a 3x NF-κB luciferase reporter
plasmid. Transfected cells were either cultured in the absence of any additional treatment
(naïve, NA) or treated for 24 h with R848 (1 μg/ml). Luciferase enzyme activity (mean
SEM, n=3) is represented on the y-axis as fold change relative to vehicle. Comparisons
between treatment groups were analyzed using a 2-way ANOVA followed by a Dunnett’s
Multiple Comparison post test. Asterisks, “***” denote significance compared to the
corresponding vehicle set to 1 at p<0.001

We also designed an experiment to check if the unexpected inhibitory effect of
R848 on hs1,2 is just limited to R848 or includes other aspects of B-cell stimulation such
as CpG, a ligand for TLR 9. CpG inhibits the basal activity of the human hs1,2 enhancer
in the same way as R848. This result indicates that B-cell activation, in general, inhibits
the basal activity of the human hs1,2 enhancer suggesting that the hs1,2 enhancer is a
negative regulator of the 3'IgHRR (Fig 11). According to these results, human hs1,2
enhancer clearly inhibited by both R-848 and CpG, with CpG being superior for hs1,2
enhancer inhibition compared to R-848.
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Figure 11: R848 and CpG inhibit basal activity of human hs1,2 and TCDD
reverses this inhibition. CL-01 cells were transiently transfected with α1A, α1B, α1C, or
α1D luciferase reporter plasmids luciferase reporter plasmid. Transfected cells were
either cultured in the absence of any additional treatment (naïve, NA) or treated for 24 h
with 0.01% DMSO vehicle (0 nM TCDD) or TCDD (30 nM) in the absence or presence
of R848 (1 µg/ml) or CpG (5 nM) stimulation. Luciferase enzyme activity (mean ± SEM,
n=3) is represented on the y-axis as relative light units normalized to transfection
efficiency. Comparisons between treatment groups were analyzed using a 1-way
ANOVA followed by a Dunnett’s Multiple Comparison post test. Asterisks, “*”, “**”, or
“***” denote significance compared between untreated to the corresponding R848 and
CpG stimulated with vehicle (0 nM TCDD) or TCDD (30 nM) at p<0.05, p<0.01 or
p<0.001, respectively. Also, “††” denotes significance compared between R848stimulated (0 nM TCDD) and R848- stimulated (30 nM TCDD) at p<0.01.
.
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AhR Antagonist (AhRA) inhibits basal and TCDD-induced human hs1,2
enhancer activity
The AhR antagonist (AhRA) was used to test if AhR is necessary for TCDDinduced activation of the human polymorphic hs1,2 enhancer in the human CL-01 cell
line. The AhRA functions by sequestering AhR in the cytoplasm upon binding to the
receptor (Kim et al., 2006). CL-01 cells were transiently transfected with the hs1,2
reporters (α1A, α1B, α1C, and α1D) then treated with the AhRA. Unexpectedly, AhRA
inhibited basal activity of the hs1,2 enhancer and TCDD reversed this inhibition (Figure
12). Interestingly, R848 increased IgG secretion but did not affect IgM secretion (Brooke
Johnson data not shown). Overall, the results indicate that the AhR is very important in
mediating TCDD’s effect on the human hs1,2 enhancer and AhR may also be an
important biological regulator of hs1,2.
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Figure 12: AhR Antagonist (AhRA) inhibits basal and TCDD-induced
human hs1,2 enhancer activity. CL-01 cells were transiently transfected with the α1B
luciferase reporter plasmid. Transfected cells were either cultured in the absence of any
additional treatment (naïve, NA) or stimulated with R848 (1 μg/ml), then treated for 24 h
with 0.05% DMSO vehicle or TCDD (0.03, 30 nM) in the absence or presence of AhRA
(30 μM). Luciferase enzyme activity (mean SEM, n=3) is represented on the y-axis as
relative light units normalized to transfection efficiency. C represents the R848 alone
control. Comparisons between treatment groups were analyzed using a 1-way ANOVA
followed by a Dunnett’s Multiple Comparison post test. Asterisks, “*”, “**”, or “***”
denote significance compared to the corresponding unstimulated vehicle control at
p<0.05, p<0.01 or p<0.001, respectively. “†” or “††”denote significance compared to the
corresponding stimulated vehicle control at p<0.05, or p<0.01, respectively
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DISCUSSION
TCDD targets Ig expression and decreases Ig heavy and light chain transcription
in mouse B-cells. Although, the AhR signaling pathway seems to mediate TCDD’s effect
on gene expression, the mechanism of TCDD’s inhibitory effect on Ig expression is still
unclear (Sulentic & Kaminski, 2011) .The mouse Igh locus, which codes for the heavy
chain of antibodies, contains several regulatory elements including the 3’IghRR region,
which contains four enhancers (hs3A; hs1,2; hs3B; and hs4) (Pinaud et al., 2011). Our lab
identified the mouse 3’IghRR as a sensitive target of TCDD-induced inhibition and
TCDD-induced AhR binding to dioxin responsive elements (DRE) in the mouse hs1,2
and hs4 enhancers (Sulentic et al., 2000; Sulentic, Zhang, et al., 2004). In addition, by
using a competitive AhR antagonist (CH-223191) and knock down of AhR protein levels,
our lab confirmed that TCDD-induced inhibition of mouse Igh expression is mediated by
an AhR-dependent mechanism, in that preventing AhR activation by TCDD fully
reversed TCDD-induced inhibition of 3’IghRR and antibody secretion (Wourms,
Sulentic, in revision).
There is some uncertainty as to whether the experimental results from mouse
3`IghRR studies can be translated to the human IgH gene. The human IgH locus contains
a duplication of the 3’IgHRR (α1 3’IgH RR and α2 3’IgH RR) and each region has three
enhancers (hs3; hs1,2; and hs4) (Pinaud et al., 2011). Additionally the α1 hs1,2 enhancer
is polymorphic and has one to four 53 bp invariant sequences. The invariant sequence
contains several transcription factor binding sites including DRE, NF-κB, SP-1, NF-1 and
AP-1 (Frezza, Rubino IA et al. 2009). Interestingly, the hs1,2 enhancer polymorphism
has been associated with several autoimmune diseases such as IgA nephropathy, celiac
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disease, systemic sclerosis, plaque psoriasis, psoriatic arthritis, dermatitis herpetiformis,
and rheumatoid arthritis (Aupetit et al., 2000; Cianci et al., 2008; Pinaud et al., 2011;
Tolusso et al., 2009). Furthermore, previous work in our lab demonstrated a species
difference between the mouse and human hs1,2 enhancer under the effects of TCDD
using the well-characterized CH12.LX mouse B-cell line model. Notably, TCDD
inhibited mouse hs1,2 enhancer activation and activated basal human hs1,2 enhancer
activity (Fernando, Ochs et al. 2012). Recently, our lab discovered that the NF-1 binding
site could be involved in the TCDD-induced activation of the human hs1,2 enhancer.
Mutation of the NF-1 binding site in the human hs1,2 enhancer decreased TCDD-induced
activation. Also, others have shown a direct interaction between Sp1, NF-κB, or AP-1
and the AhR/ARNT complex (Kobayashi, Sogawa, & Fujii-Kuriyama, 1996).We
speculate that potential protein-protein interactions between the transcription factors that
bind within the hs1,2 enhancer are sensitive to environmental influences (i.e. exposure to
dioxin and other AhR ligands, etc.) leading to altered hs1,2 activity and Ig expression.
Our current results suggest a dominant role of the AhR and NF1 in TCDD-induced
activation of the human hs1,2 enhancer, but does not rule out a contribution of the other
transcription factors binding within the hs1,2 enhancer (data not published). Activation of
the human hs1,2 enhancer by TCDD may provide a link between the human hs1,2
enhancer and the above mentioned autoimmune diseases. In other words, AhR ligands
could alter human 3'IgHRR activity through the hs1,2 enhancer and potentially modulate
disease states associated with the hs1,2 polymorphism, particularly due to the fact that
most of the transcription factors binding site within the invariant sequence have been
shown to be modulated by TCDD (Frericks, Burgoon, Zacharewski, & Esser, 2008;

41

Sulentic et al., 2000). Furthermore, a functional humoral immune response requires Bcell activation and previous studies with mouse or human B cells have demonstrated an
increase in AhR protein levels due to cellular activation (Marcus, Holsapple, &
Kaminski, 1998; Sherr & Monti, 2013). For that reason, increased AhR expression in
activated B cells and differences in the number of AhR binding sites in the hs1,2 alleles
may influence individual sensitivity to AhR ligands and to autoimmune diseases
associated with the polymorphic hs1,2 enhancer. However, studies to date have been
limited to examining the human hs1,2 enhancer in the well-characterized CH12.LX
mouse B-cell model. Therefore, the objective of this study was to elucidate the effects of
TCDD and cellular stimulation on the polymorphic human hs1,2 enhancer in a human Bcell line (CL-01) and to determine if these effects are AhR dependent and similar to
previous results using the CH12.LX mouse model.
As seen in the CH12.LX cells, the current results demonstrate TCDD-induced
activation of the human polymorphic hs1,2 luciferase reporter constructs in the CL-01
human B-cell line. However, activation of the human hs1,2 enhancer contrasts markedly
with the inhibitory effect of TCDD on human IgM and IgG secretion (Fig.7 and Brooke
Johnson, unpublished data). On the other hand, cellular activation through TLR7/8 or 9
via R848 or CpG, respectively, inhibits human hs1,2 enhancer activity, which also
contrasts with the induction of IgM and IgG secretion by R848 (Fig.12 and Brooke
Johnson, unpublished data, summarized in Fig. 13 and 14). R848 has been reported to
activate immune cells, including neutrophils, T cells, dendritic cells, and B cells (Tomai
MA, Waldschmidt TJ et al. 2000 North, Crawford et al. 2010), which corresponds to the
activation of IgM and IgG secretion in the CL-01 cells. However, the inhibition of the
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human hs1,2 enhancer by R848 not only contrasts with the effects on Ig secretion but also
contrasts with the effects in the mouse B cell line where LPS stimulation activated the
human and mouse hs1,2 enhancers. Perhaps there are differences in TLR signaling
pathways between human and mouse or different TLR pathways influence the human
hs1,2 enhancer differently. R848 activates human B cells through TLR7/8 while LPS
activates mouse B cells through TLR4, which is not present in human B cells. TLR7/8
activation may have a different mechanism than TLR4 has on the hs1,2 enhancers.
Interestingly, R848 and CpG have no effect on the human hs1,2 enhancer activity when
evaluated in the mouse B cell line CH12.LX (data not published) which lead us to believe
that the differences in hs1,2 activation are related to species difference in TLR signaling
pathways. Furthermore, R848 (TLR7/8) and CpG (TLR9) increased NF-κB activation in
the CL-01 cells, which was consistent with the effects of these stimuli on Ig secretion.
However, the effect of these stimuli on other transcriptions factors that may bind within
the human hs1,2 enhancer have not been evaluated. Therefore, future studies should
focus on evaluating the different TLR signaling pathways in human and mouse cells to
identify any differences in the activation of transcriptions factors such as AP-1, AhR,
Sp1, and NF-1 or any differences in the levels of TLR expressed following TLR
activation and/or TCDD treatment.
The basal activity of the enhancer increases along with increasing numbers of 53
bp invariant sequences in the human hs1,2 enhancer with the exception of the α1D allele
(four IS). The basal activity of α1D is the same as α1B (α1A < α1B ~ α1D < α1C). Each 53 bp
IS has many transcription factor binding sites such as NFκB, NF-1, AP-1, and DRE.
TCDD-activated AhR could bind the DRE binding site to directly increase the basal
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activity of the hs1,2 enhancer or the AhR could alter the signaling pathway of other
transcription factors associated with the hs1,2 enhancer. The lower basal activity of α1D
could be because not all binding sites, especially the DRE located in the fourth repeat, are
conserved. To better evaluate the impact of the fourth repeat and of potential binding
sites within the human polymorphic hs1,2 enhancer, mutational analysis of the α1D human
hs1,2 reporter construct should be performed in which the non-conserved binding sites
(i.e. DRE) are mutated to be identical to the conserved sites within the other allele. This
would determine if loss of conserved sites has a functional impact. Secondly, we could
delete the fourth IS repeat in the α1D allele and see if the reporter after deletion behaves
like the α1C under the effects of TCDD and R848. If it is the same then the fourth repeat
is not as active as the first three repeats. Also the fourth 53 bp IS may even be inhibitory
since α1C has more activity than the α1D.
As previously mentioned, R848 and CpG both inhibit the hs1,2 enhancer.
Interestingly, CpG is a stronger inhibitor than R848 and TCDD reverses the R848
inhibitory effect but not that of CpG. These data might suggest that CpG and therefore
TLR9 activation inhibits the human hs1,2 enhancer through NFκB and AP-1(Kawai &
Akira, 2006), and additional differences in TLR signaling pathways. Alternatively, CpG
could induce a greater NFκB response and a stronger inhibitory signal for the hs1,2
enhancer that is too powerful for a 30 nM TCDD treatment to reverse. To test this theory,
a CpG concentration response with a fixed 30 nM

TCDD concentration

would

determine if the increased inhibitory effect of CpG is due to pharmacokinetic rather than
pharmacodynamic reasons.
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AhR is a protein located in the cytosol in an inactive form bound to a dimer of the
HSP90 molecules, p23, and XAP2. Upon TCDD binding, the AhR becomes active and
translocates to the nucleus to bind with ARNT and either directly or indirectly influences
the hs1,2 enhancer and the 3'IgHRR. It is still unclear whether binding of the
TCDD/AhR/ARNT complex to DREs or to other transcription factors affects the basal
activity of the human hs1,2 enhancer. Therefore, it was very important to characterize the
role of the AhR on the hs1,2 enhancer to determine if TCDD-induced inhibition of IgH is
mediated by an AhR-dependent activation of the human hs1,2 enhancer. Using a
competitive AhR antagonist (AhRA), we demonstrated inhibition of basal and TCDDinduced hs1,2 activity. However, other studies in our lab demonstrated a surprising result
where the AhRA increased the levels of R848-induced IgG secretion with no effect on
IgM secretion (Brooke Johnson, unpublished data). On the other hand, AhRA
unexpectedly inhibited basal activity of the hs1,2 enhancer and TCDD reversed this
inhibition (Fig. 14). By using TCDD, AhR becomes activated and translocates to the
nucleus and activates the hs1,2 enhancer but inhibits IgM and IgG secretion. The AhRA,
on the other hand, competes with TCDD to keep the AhR in the cytosol in its inactive
form resulting in no activation of the hs1,2 enhancer and no inhibition of IgG secretion.
Surprisingly, the AhRA in the absence of TCDD inhibited basal hs1,2 enhancer activity
and increased IgG secretion suggesting endogenous activation of the AhR perhaps by an
as of yet unidentified endogenous ligand. This data indicates that the effects of TCDD on
the human polymorphic hs1,2 enhancer may be mediated by the AhR and that some level
of endogenous AhR activity is present that may inhibit CSR from IgM to IgG. Taken
together, these results support our hypothesis that the AhR is a negative regulator of class
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switch recombination (CSR) and Ig expression. Additional studies are necessary to
confirm a physiological role of the AhR in CSR and Ig expression including knocking
down the AhR using shRNA and thoroughly evaluating the effect of less AhR on the
complicated CSR process in the CL-01 cells.
In conclusion, the present study has evaluated the human hs1,2 enhancer in
human cells under TCDD. Interestingly, the polymorphisms in the human hs1,2
enhancer, which results in a varying number of tandem repeats of a 53 bp sequence,
correlate with a number of immune disorders, such as plaque psoriasis, psoriatic arthritis,
systemic sclerosis lupus, rheumatoid arthritis, celiac disease, herpetiform dermatitis, and
IgA nephropathy (Aupetit, Drouet et al. 2000, Cianci, Giambra et al. 2008, Tolusso,
Frezza et al. 2009, Pinaud, Marquet et al. 2011). Elucidating the role of the polymorphic
hs1,2 enhancer in 3’IgHRR activity and the effect of TCDD on the enhancers of the
3’IgHRR may provide insights into the etiology of autoimmune diseases associated with
the hs1,2 polymorphism. Previous work from the lab identified the mouse 3’IghRR as a
sensitive target of AhR ligands including TCDD and non-dioxin ligands such as ICZ,
primaquine, carbaryl, and omeprazole. These non-dioxin chemicals have the same
inhibitory effect as TCDD on both 3’IghRR activation and Igh protein expression
(Sulentic 2008). Also, our studies with an AhR antagonist strongly support an important
role for AhR ialsoalson the effects of TCDD on human hs1,2 activity. Interestingly α1B
increased severity of several autoimmune diseases such as IgA nephropathy, celiac
disease, systemic sclerosis, plaque psoriasis, psoriatic arthritis, dermatitis herpetiformis,
and rheumatoid arthritis (Aupetit, Drouet et al. 2000, Cianci, Giambra et al. 2008,
Tolusso, Frezza et al. 2009, Pinaud, Marquet et al. 2011), which could be altered by AhR
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ligands. This work demonstrates Ig expression and CSR can be modulated by AhR
ligands through the 3’IgHRR.Therefore non-persistent AhR ligands that do not produce
the plethora of toxicities produced by TCDD could provide insight in designing an AhR
ligand drug for autoimmune diseases (Hu et al., 2007).
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Figure 13. Contradictory effects of TCDD versus cellular stimulation through TLR on the
the human polymorphic hs1,2 enhancer and Ig expression in the CL-01 human B cell line
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Figure 14. Contradictory effects of TCDD versus AhR agonists on the human
polymorphic hs1,2 enhancer and Ig expression in the CL-01 human B cell line.
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